NTRK (Neurotrophic receptor tyrosine kinase)

P2, N=39, Recruiting, University of Chicago | Not yet recruiting --> Recruiting

The patient was treated with temozolomide concurrently with radiotherapy, followed by tumor treating fields with adjuvant temozolomide...Various tyrosine kinase inhibitors, including entrectinib, larotrectinib, repotrectinib, and selitrectinib, along with bevacizumab, were considered to potentially prolong progression-free survival and overall survival and improve quality of life. We expect to highlight the rarity of this case while discussing the effectiveness of second-generation tyrosine kinase inhibitors in high-grade glioblastomas with rare gene fusions. We also hope to identify the appropriate timeline and treatment sequence for post-standard care, given the lack of official guidelines regarding cases this infrequent.

P2, N=45, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: May 2028 --> May 2027

Our findings expand the morphological and immunohistochemical spectrum of NTRK-rearranged uterine sarcomas, highlight important diagnostic pitfalls and raise the important question of driver versus passenger molecular events. Recognition of tumours with these unusual features is crucial, as NTRK-rearranged sarcomas frequently show aggressive clinical behaviour but are potentially amenable to targeted therapy with selective TRK inhibitors.

RET fusions and genetic alteration combination are independent prognostic markers for tumor recurrence of PTC, integrating tumors' genetic status into the 2025 ATA RSS system improves the accuracy of risk stratification for PTC.

P3, N=195, Recruiting, InnoPharmax Inc. | Not yet recruiting --> Recruiting

Recent developments in personalized medicine, including the introduction of new molecular diagnostic tools and targeted agents, have made considerable progress in the risk stratification and treatment strategies for papillary thyroid carcinoma. The current article reviews molecular mechanisms of activation of MAPK and PI3K/AKT pathways, their interaction, clinicopathological importance, and targeted treatments in papillary thyroid carcinoma.

P2, N=152, Not yet recruiting, The Third Xiangya Hospital of Central South University

Molecular testing frequently revealed targetable alterations in patients with advanced TC, and matched therapies yielded meaningful clinical benefit. These findings underscore the value of precision medicine in TC and support broader implementation of molecular-guided treatment strategies.

The approach emphasizes (i) selecting a thyroid-appropriate molecular assay from the outset whenever feasible, (ii) explicitly documenting residual suspicion and the scope of the performed assay in pathology reports, (iii) using pan-TRK immunohistochemistry only as an optional triage tool rather than a rule-out test, and (iv) considering RNA-based or other fusion-optimized assays only when the original clinical question remains unresolved and the result is clinically relevant. This framework is intended to reduce false reassurance from negative limited panels while reinforcing the need for appropriate molecular testing in the correct clinical scenario.

Continuous genomic monitoring is essential for identifying resistance mechanisms and guiding precision therapy. Future studies should explore the impact of different fusion partners on tumor behavior and therapeutic response.

These findings highlight non-tobacco environmental exposures in young lung cancer and support further investigation of dietary patterns and hormonal factors in mutation-specific disease pathways.